Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
51,954,100
-
Shares change
-
+3,544,171
-
Total reported value, excl. options
-
$856,215,990
-
Value change
-
+$74,681,603
-
Put/Call ratio
-
86.95%
-
Number of buys
-
55
-
Number of sells
-
-39
-
Price
-
$16.48
Significant Holders of AVADEL PHARMACEUTICALS - COM (AVDL) as of Q2 2023
129 filings reported holding AVDL - AVADEL PHARMACEUTICALS - COM as of Q2 2023.
AVADEL PHARMACEUTICALS - COM (AVDL) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51,954,100 shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (7,522,545 shares), RTW INVESTMENTS, LP (6,810,641 shares), GENDELL JEFFREY L (5,396,060 shares), Polar Capital Holdings Plc (4,534,921 shares), Vivo Capital, LLC (3,829,577 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,680,000 shares), COWEN AND COMPANY, LLC (2,664,076 shares), WEALTH EFFECTS LLC (2,369,089 shares), Woodline Partners LP (1,879,343 shares), and BRANDES INVESTMENT PARTNERS, LP (1,289,195 shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.